STEP TEENS trial: Semaglutide in adolescents reduces weight and improves liver health
Two new secondary analyses of the STEP TEENS trial presented at this year's European Congress on Obesity have reported that almost half...
top of page
Browse by category
Search
Anti-obesity medications remain prohibitively expensive
Several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to...
Top 10 most read articles on Bariatric News - September 2022
It has been another busy month reporting the latest bariatric and metabolic, and obesity-related disease news. We hope we have brought...
Semaglutide is clinically effective for weight loss at three and six months
Researchers from the Mayo Clinic, Rochester, MN and the Mayo Clinic, Jacksonville, FL, have reported findings from a cohort study that...
NICE recommends semaglutide for obesity treatment
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more...
STEP 2: Semaglutide aids weight loss in type 2 diabetics
Type 2 diabetics treated with a weekly injection of Semaglutide were able to achieve an average weight loss of nearly 10 kg, according to...
Semaglutide plus intensive behavioural therapy showed triple weight loss vs placebo
A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier...
STEP outcomes: Semaglutide could be ‘gamechanger’ in battle against obesity
One third (35%) of patients who received semaglutide for treating obesity lost more than one-fifth (greater than or equal to 20%) of...
Browse by tag
bottom of page